NADMED has appointed James Lee as its new Chief Executive Officer, effective from the beginning of May. His appointment supports the company’s next phase of international growth and expansion.
Lee brings over 25 years of experience in global pharma and healthcare, including senior roles at Novo Nordisk and Pharmanovia, and will help scale NADMED’s technology across research, diagnostics, and clinical applications.
Current CEO and co-founder Jari Närhi will step down and continue in an advisory role to support the transition.
Read the press release here.